Flortaucipir
As of the edition of 20 October 2026, Flortaucipir is a small molecule: marketed, first approved in 2020 (US); acts on MAPT; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Tauvid
- First approved
- 28 May 2020 (US)
- Approvals on record
- 6 in 3 regions
- Holder of the most recent approval
- PDRadiopharma Inc.; 3 holders in all
- Registered trials
- 48, 5 stopped early
- Disease areas
- Nervous system; Mental health; Injuries; Nutrition and metabolism; Blood and lymph; Cancer
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Avid Radiopharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product4 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 4 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Flortaucipir.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAPT | Microtubule-associated protein tau | P10636 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 5 | 7 | 1 |
| Phase 1 | 17 | 12 | 3 | 2 |
| Phase 2 | 10 | 7 | 1 | 2 |
| Phase 3 | 5 | 4 | 1 | 0 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 48 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Avid Radiopharmaceuticals | Originator and Lead sponsor of trials | 2013 to now |
| Eli Lilly | Applicant and Lead sponsor of trials | 2017 to now |